在慢性淋巴细胞白血病患者中，使用布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼治疗期间，12号染色体三体与淋巴细胞再分布缩短相关。 - Suppr | 超能文献

相似文献

1

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.在慢性淋巴细胞白血病患者中，使用布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼治疗期间，12号染色体三体与淋巴细胞再分布缩短相关。

Br J Haematol. 2015 Jul;170(1):125-8. doi: 10.1111/bjh.13269. Epub 2014 Dec 18.

2

Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.描述单药伊布替尼治疗慢性淋巴细胞白血病患者淋巴细胞增多的动力学特征。

Leuk Lymphoma. 2019 Apr;60(4):1000-1005. doi: 10.1080/10428194.2018.1512710. Epub 2018 Oct 2.

3

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.依鲁替尼治疗复发或难治性慢性淋巴细胞白血病患者的真实世界结果：来自一项同情用药项目中连续治疗的95例患者的数据。瑞典慢性淋巴细胞白血病研究组的一项研究。

Haematologica. 2016 Dec;101(12):1573-1580. doi: 10.3324/haematol.2016.144576. Epub 2016 May 19.

4

Long-Term Ibrutinib Therapy Reverses CD8 T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia.长期伊布替尼治疗可逆转 B 细胞慢性淋巴细胞白血病中 CD8 T 细胞耗竭。

Front Immunol. 2019 Dec 12;10:2832. doi: 10.3389/fimmu.2019.02832. eCollection 2019.

5

Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?依鲁替尼治疗慢性淋巴细胞白血病患者的感染情况：关联有多强？

Eur J Haematol. 2018 Sep;101(3):418-420. doi: 10.1111/ejh.13098. Epub 2018 Jun 22.

6

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.伊布替尼用于复发/难治性慢性淋巴细胞白血病：英国和爱尔兰315例患者的疗效分析。

Haematologica. 2016 Dec;101(12):1563-1572. doi: 10.3324/haematol.2016.147900. Epub 2016 Oct 18.

7

Ibrutinib-Induced Lymphocytosis: Cytological Features.依鲁替尼诱导的淋巴细胞增多症：细胞学特征

Acta Haematol. 2017;137(1):55-57. doi: 10.1159/000452437. Epub 2016 Dec 14.

8

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.伊布替尼治疗慢性淋巴细胞白血病患者完全缓解的预后因素：2 项临床试验的汇总分析。

JAMA Oncol. 2018 May 1;4(5):712-716. doi: 10.1001/jamaoncol.2017.5604.

9

ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.ALPINE 研究：泽布替尼对比伊布替尼用于复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。

Future Oncol. 2020 Apr;16(10):517-523. doi: 10.2217/fon-2019-0844. Epub 2020 Mar 24.

10

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.3 项关键性研究中单药伊布替尼治疗慢性淋巴细胞白血病患者的长期安全性。

Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761.

引用本文的文献

1

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.黏附、迁移和激活分子的表达调控可能预测接受依鲁替尼加利妥昔单抗治疗的慢性淋巴细胞白血病患者的反应程度。

Haematologica. 2020 Oct 5;106(5):1500-1503. doi: 10.3324/haematol.2020.262071.

2

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.化疗免疫疗法和新型靶向疗法背景下慢性淋巴细胞白血病当前预后和预测生物标志物的最新观点

Cancers (Basel). 2020 Apr 7;12(4):894. doi: 10.3390/cancers12040894.

3